Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

r placebo (n=118). Significantly more patients in the desvenlafaxine succinate group responded to treatment compared with the placebo group (51 percent vs. 32 percent, respectively) at the final study evaluation. When individual items from the HAM-D17 were analyzed, desvenlafaxine succinate patients experienced a statistically significant improvement in depressed mood, psychic anxiety, general somatic symptoms and suicidal thoughts. Treatment-emergent adverse events reported in this study were consistent with the SNRI class and included nausea, dry mouth, insomnia, somnolence, sweating, anorexia (loss of appetite), tremor and impotence.

About Desvenlafaxine

Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) studied as a potential treatment for adult men and women with MDD. Wyeth submitted a New Drug Application (NDA) for MDD on December 22, 2005. The Company also has filed an NDA for vasomotor symptoms (VMS) associated with menopause and expects a U.S. Food and Drug Administration (FDA) action letter in the third quarter of 2007. If approved, desvenlafaxine will be the first and only non-hormonal medicine for the treatment of VMS associated with menopause. Wyeth is a leader in both neuroscience and women's health care.

Wyeth discovered and developed the first SNRI approved by the FDA, which currently is the most widely used antidepressant in the world. Desvenlafaxine represents Wyeth's latest efforts and continued commitment to developing therapies to help improve the lives of patients suffering from mental health disorders.

According to a large depression trial funded by the National Institute of Mental Health, only 28 percent of patients with depression achieved remission with initial antidepressant treatment. This leaves a large percentage of patients still suffering from depression. Clearly, additional medicines are needed for treating MDD.

About Antidepressants

Antidepressants increased the risk of s
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Bevacizumab Market ,2010-2019" ... under the trade name of Avastin, bevacizumab injection is ... 2010, it was approved by CFDA to treat metastatic ... China all come from Roche and its ...
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Genomic Health, Inc . (Nasdaq: GHDX ... Executive Chairman of the Board, will present at the Piper ... November 29, 2011 at 1:30 p.m. Eastern Time (ET).   ... of the presentation, visit the Investor Relations section of Genomic ...
... Nov. 22, 2011 Frost & Sullivan honors ... Sullivan 2011 North American Technology Innovation Award in ... VoXcell ® Imaging Suite.  For the first ... throughout the enterprise using robust industry-standard applications, leading-edge ...
Cached Medicine Technology:Genomic Health to Present at the Piper Jaffray Health Care Conference 2Genomic Health to Present at the Piper Jaffray Health Care Conference 3KJAYA Medical Honored with 2011 Frost & Sullivan Award for Technology Innovation in Web-based Medical Imaging Data Management 2
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and ... The American Heart Association hosts their well-known Heart Walk to raise money in awareness ... can be made. Walkers can participate in the cause and someone can also donate, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a ... struggling with chemical dependency, may be able to find some hope in the ... treatment center for addiction located in Western Michigan. Focusing on several different aspects ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Medical Solutions, ... 2015 Best Places to Work in Healthcare by Modern Healthcare and will ... , Now in its eighth year, the Best Places to Work in Healthcare ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ground ... the Food and Drug Administration to eliminate submental fat, also known as the double ... among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , Developed ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... is dedicated to distributing health information technology innovation to transform quality and efficiency ... of the survey will be de-identified and aggregated before being publicly shared to ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
... Nov. 30 Mary Rita Hyland, Assistant Vice President of ... elected to the 2010 Board for the Workgroup for Electronic ... of leadership positions at SSI since joining the organization in ... of the Quality Assurance division and Business Continuity for SSI. ...
... of ,stroke belt, study finds , MONDAY, ... belt" of the southern United States have a lifelong higher ... live elsewhere later, a new study shows. , Data on ... South Carolina, Georgia, Tennessee, Arkansas, Mississippi and Alabama show a ...
... , LOS ANGELES, ... as a woman, and brings with it a host of uncomfortable ... mood swings, weight gain , night sweats and lethargy are ... worse, menopause signs and symptoms can show up a ...
... , ... , NEW YORK, Nov. 30 Distance runners who live at ... races in areas that are at sea level. Can heart failure ... tent-like, high-altitude simulator? , That is the question being studied among 15 heart ...
... Fla., Nov. 30 The launch of Invivo Corporation,s ... FDA-cleared, fully-automated morphological system for the detection and analysis ... system will be officially unveiled at the Radiological Society ... Developed in partnership with leading experts in breast MRI, ...
... safe transplant results in animals , MONDAY, Nov. 30 (HealthDay ... cells from transplanted human-derived umbilical cord blood could help treat ... that such stem cells can differentiate into a long list ... Soon Park of the Samsung Medical Center in Seoul, Korea, ...
Cached Medicine News:Health News:SSI Assistant Vice President Elected to WEDI Board 2Health News:Birth in South Raises Stroke Risk for Life 2Health News:Birth in South Raises Stroke Risk for Life 3Health News:Anti-Aging Institute of California Offers New Natural Solution for Menopause Symptoms 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 3Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 4Health News:New Breast MRI Technology Enables Enhanced Breast Cancer Detection 2Health News:New Breast MRI Technology Enables Enhanced Breast Cancer Detection 3
Microcontroller-based isolated electrosurgical generator, designed for all general purpose surgical procedures. Unit includes: Instant Response technology, adaptive REM system, isolated output, CEM c...
Maddox rod and occluder...
Long handle occluder - White...
Double Ended Occluders...
Medicine Products: